1249 / 1631
Median observation time
(range), months*
37.0 (0.6–54.4)
40.8 (0.2–52.8)
Number of PFS (INV)
events (%)
21 (21.2)
26 (27.1)
HR for PFS (INV), G vs R
(95% CL), p
‐
value
†
0.82 (0.45, 1.46), p=0.49
HR for other time
‐
to
‐
event endpoints, G vs R (95% CL), p
‐
value
†
PFS (IRC)
‡
0.83 (0.46, 1.51), p=0.55
Overall survival
0.90 (0.45, 1.81), p=0.78
Time to new anti
‐
lymphoma
treatment
0.85 (0.48, 1.50), p=0.57
Response at EOI by CT (INV)
CR, n (%)
16 (16.2)
18 (18.8)
ORR, n (%)
82 (82.8)
78 (81.3)